Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007
- 13 February 2012
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (8) , 1488-1493
Abstract
A retrospective analysis was done using the Surveillance, Epidemiology, and End-Results (SEER) database to determine the trends in overall survival and identify prognostic factors in patients with mantle cell lymphoma (MCL). In total 5367 cases of MCL identified from 1992 to 2007 were split into three cohorts, group 1(1992–1999), group 2 (2000–2003) and group 3 (2004–2007). Survival was analyzed using the Cox proportional hazards model to correct for age, gender and stage of disease. The proportion of patients with advanced disease at diagnosis, male gender and advanced age increased over time and these were all associated with increased mortality. The overall survival remained unchanged. However, when adjusted for the increased proportion of patients with poor prognostic features noted above, we found a significant improvement in survival. The adjusted model also showed an improvement in predicted survival over time in patients with advanced stage. No change in survival was seen in patients with localized disease. Although this analysis is not designed to evaluate specific treatment modalities, these data suggest that the development of new treatment strategies over the past decade may be impacting the survival of patients with advanced MCL despite the finding that the overall survival remains unchanged in the general US population.Keywords
This publication has 19 references indexed in Scilit:
- Improvement of Overall Survival in Advanced Stage Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood, 2008
- Therapy of Mantle Cell Lymphoma: Current Standards and Future StrategiesHematology/Oncology Clinics of North America, 2008
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004Cancer, 2008
- High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and CytarabineJournal of Clinical Oncology, 2005
- Cytogenetic Findings in Mantle Cell LymphomaAmerican Journal of Clinical Pathology, 2001
- Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenström's Macroglobulinemia, and Mantle-Cell LymphomaJournal of Clinical Oncology, 1999
- Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.Journal of Clinical Oncology, 1998
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Mantle Cell Lymphoma A Proposal for Unification of Morphologic, Immunologic, and Molecular DataAmerican Journal of Surgical Pathology, 1992